What does this research mean for the field?

Lazertinib demonstrates significant intracranial efficacy in patients with EGFR-mutated non-small cell lung cancer and central nervous system involvement who have previously progressed on EGFR tyrosine kinase inhibitors, regardless of T790M mutation status. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the intracranial and systemic efficacy of lazertinib in patients with EGFR-mutated non-small cell lung cancer and central nervous system involvement following prior EGFR tyrosine kinase inhibitor therapy.

September 2, 2026Thoracic CancerOpen Access

Central Nervous System Activity of Lazertinib in EGFR ‐Mutated NSCLC With Prior EGFR TKI Exposure: A Pooled Analysis of KCSG‐LU20‐15 and LU21‐01

View Full Paper

Ask AI

Bookmark

Authors

DKDong Hyun Kim MHMin Hee Hong HJHyun Ae Jung

Discussion

Member takes

Overview

Pooled phase II analysis demonstrates durable intracranial activity of lazertinib in pretreated EGFR-mutated NSCLC, highlighting its potential against central nervous system metastases.

Key Points

To evaluate the intracranial and systemic efficacy of lazertinib in patients with EGFR-mutated non-small cell lung cancer and central nervous system involvement following prior EGFR tyrosine kinase inhibitor therapy.
Pooled analysis of 72 patients with EGFR-mutated NSCLC and CNS involvement from two Phase II clinical trials (KCSG-LU20-15 and KCSG-LU21-01) with prior EGFR TKI exposure.
Assessed intracranial and overall objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).
Among 46 evaluable patients, intracranial ORR was 50.0%, intracranial DCR was 97.8%, and median intracranial PFS reached 15.2 months.
Among 66 patients evaluable for systemic response, overall ORR was 22.7%, DCR was 97.0%, median PFS was 10.6 months, and median OS was 17.8 months.
Patients with leptomeningeal metastases had inferior survival outcomes compared to those without, while outcomes did not significantly differ by T790M mutation status.

Cite This Study

Kim et al. (2026) studied this question.

synapsesocial.com/papers/6a97e2f6c562ede874ec771c https://doi.org/10.1111/1759-7714.70387

View Full Paper

Ask AI

Bookmark

September 2, 2026Thoracic CancerOpen Access

Central Nervous System Activity of Lazertinib in EGFR ‐Mutated NSCLC With Prior EGFR TKI Exposure: A Pooled Analysis of KCSG‐LU20‐15 and LU21‐01

View Full Paper

Ask AI

Bookmark

Authors

DKDong Hyun Kim MHMin Hee Hong HJHyun Ae Jung

Discussion

Member takes

Overview

Pooled phase II analysis demonstrates durable intracranial activity of lazertinib in pretreated EGFR-mutated NSCLC, highlighting its potential against central nervous system metastases.

Key Points

To evaluate the intracranial and systemic efficacy of lazertinib in patients with EGFR-mutated non-small cell lung cancer and central nervous system involvement following prior EGFR tyrosine kinase inhibitor therapy.
Pooled analysis of 72 patients with EGFR-mutated NSCLC and CNS involvement from two Phase II clinical trials (KCSG-LU20-15 and KCSG-LU21-01) with prior EGFR TKI exposure.
Assessed intracranial and overall objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).
Among 46 evaluable patients, intracranial ORR was 50.0%, intracranial DCR was 97.8%, and median intracranial PFS reached 15.2 months.
Among 66 patients evaluable for systemic response, overall ORR was 22.7%, DCR was 97.0%, median PFS was 10.6 months, and median OS was 17.8 months.
Patients with leptomeningeal metastases had inferior survival outcomes compared to those without, while outcomes did not significantly differ by T790M mutation status.

Cite This Study

Kim et al. (2026) studied this question.

synapsesocial.com/papers/6a97e2f6c562ede874ec771c https://doi.org/10.1111/1759-7714.70387

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark